申请人:Syntex Pharmaceuticals, Ltd.
公开号:US05428037A1
公开(公告)日:1995-06-27
Compounds of the formula: ##STR1## wherein A, R.sup.1, R.sup.2, R.sup.3 and m are defined as in the specification or a pharmaceutically acceptable acid addition salt or N-oxide thereof, are calcium and sodium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and also for treatment of spinal injuries.
式中A、R.sup.1、R.sup.2、R.sup.3和m的定义如规范中所述,或其药学上可接受的酸盐或N-氧化物,是对抗钙和钠通道的拮抗剂,用于治疗患有各种疾病状态的哺乳动物,如中风、癫痫、高血压、心绞痛、偏头痛、心律失常、血栓形成、栓塞,以及治疗脊柱损伤。